Laekna (HKG:2105) started a subcutaneous dosing cohort in its phase I single ascending dose study for its overweight and obesity treatment, according to a Friday filing with the Hong Kong bourse.
By Sept. 30, 50% of the planned groups for intravenous injection had received their doses, the filing said.
LAE102 is a specially developed antibody focusing on ActRIIA, a protein essential for muscle repair and fat processing in the body. The treatment helps gain lean muscle and decrease fat mass, according to the filing.
Price (HKD): $7.99, Change: $+1.8, Percent Change: +29.50%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments